

Doxorubicin-Loaded Polyelectrolyte Multilayer Capsules Modified with Antitumor DR5-Specific TRAIL Variant for Targeted Drug Delivery to Tumor Cells

Anastasia Gileva ^{1,*}, Daria Trushina ^{2,†}, Anne Yagolovich ^{1,3,†}, Marine Gasparian ¹, Leyli Kurbanova ¹, Ivan Smirnov ¹, Sergey Burov ⁴ and Elena Markvicheva ¹

¹ Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry RAS, 117997 Moscow, Russia

² Laboratory of Bioorganic Structures, Shubnikov Institute of Crystallography of Federal Scientific Research Centre “Crystallography and Photonics” of Russian Academy of Sciences, Moscow 119333, Russia

³ Faculty of Biology, Lomonosov Moscow State University, 119192 Moscow, Russia

⁴ Cytomed JSC, Orlovo-Denisovsky pr. 14, St. 197375 Petersburg, Russia,

* Correspondence: sumina.anastasia@mail.ru; Tel.: +79164517818

† These authors contributed equally to this work




Figure S1. ζ-potential distributions for intact (Parg/DS)₃ capsules (a), (Parg/DS)₃ capsules after modification with targeted protein DR5-B (b), and for DR5-B protein molecules (c).




Figure S2. Cytotoxicity of free DR5-B, DR5-B/V114C and DR5-B/V114C-Cy3 for colorectal carcinoma HCT-116 monolayer cell culture. MTT-test.